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 7.1 Introduction 
 
An increase in poly substance use has been demonstrated over the past years. This 
tendency has been noticeable in society, but has also been observed among 
substance users who ask for treatment in specific drug treatment services. 
However, information of service providers in Belgium is rather limited. 
Therefore, the specific aims of this study were to determine the prevalence of poly 
substance use in an integrated sample of substance users, seeking treatment in 
psychiatric hospitals, long-term residential treatment settings, detoxification units 
or outpatient methadone maintenance services and to investigate variables that 
could predict poly substance use in the last 30 days. Specific attention will be given 
to the characteristics of poly substance users and the extent and type of psychiatric 
disorders in this population. 
 
 
7.2 Methods 
 
7.2.1 Sample and data selection 
 
This study is based on an integrated sample of two cross-sectional studies. The 
first study is a multi-center, cross-sectional study in 11 units for substance abuse 
treatment, situated in a psychiatric hospital in the provinces of East- and West-
Flanders (Belgium) (n=274). The methodology of this study is extensively 
described in chapter 5. The second study wad based on a clinical sample of 
individuals seeking in- or outpatient substance abuse treatment in specialised drug 
treatment settings (n=55). This study was set up in 3 types of treatment services, 
methadone maintenance treatment, detoxification and long-term residential 
treatment (e.g. therapeutic communities) in Belgium. Data were collected between 
April 1st and December 31st  2010. In order to be eligible for the study participants 
had to (a) be older than 18, (b) be able to speak Dutch or French, (c) be treated for 
 an initial drug problem. Individuals were excluded if they (a) had Korsakoff 
syndrome or limited cognitive abilities or (b) suffered from acute psychotic 
symptoms. Informed written consent was obtained from all participants prior to 
their inclusion in the study. Participation was entirely voluntary and 
confidentiality was assured. Individuals received a voucher for participation in the 
study. In total, 55 participants were interviewed in the second study during the 
nine months data collection.  
 
Table 1: Overview of treatment settings of the second sample 
Type of Treatment Setting N % 
   
Methadone maintenance treatment 25 45.4 
Detoxification  16 29.1 
Long-term residential treatment 14 27.3 
   
 
 
7.2.2 Data analysis 
  
Both samples were merged in one database and afterwards the total sample 
(n=329) was split up in two subgroups based on the presence or absence of recent 
poly-drug use (last 30 days). Poly substance use was defined as the use of different 
substances on the same day (Cf. EuropASI; Raes, Lombaert & Keymeulen, 2008). 
A descriptive profile of both, single drug users and poly substance users is 
presented including sociodemographic characteristics, substance use and 
psychological wellbeing. To test statistically significant differences between the 
single and poly substance use group, chi2-tests was applied in case of categorical 
variables (when > 20% of the cells had an expected count < 5, the Fischer’s exact 
test was used) and a t-tests for continuous variables. When the overall chi2 was 
significant, custom tables were used to evaluate which specific categories of each 
variable were significant. ASI composite scores were computed to analyse the 
severity of problems on different life domains (physical health, employment, legal 
situation, family relations, alcohol and drug use, psychological health). 
Afterwards, binary logistic regression was used to assess factors (continuous and 
categorical) independently associated with recent poly substance use (the 
dependent variable). After the bivariate comparisons by substance use group 
 (poly-drug use and single drug use) 18 predictors (variables with a p value <0.05 
(except for gender)) were initially included in the binary logistic regression model: 
gender, age, civil status, living situation, employment, legal status, mean number 
of suicide attempts, mean number of hospital admissions ever, mean number of 
convictions, living with someone with alcohol problems, ASI composite score for 
drugs, ASI composite score for employment, ASI composite score for legal status, 
ASI composite score for psychological status, having at least one personality 
disorder, having at least one anxiety disorder, having at least one mood disorder, 
suicidal risk. In a next step, the recursive feature elimination method as 
implemented by the R-package Caret (for more details, see Kuhn, 2008) was used 
to prespecify the important variables to include in our final prediction model. To 
prevent overfitting, 10-fold cross-validation was applied. Within each of the 10 
resampling iterations, whereby one sample was held back to test model 
performance, several models were fit. The process started by fitting a logistic 
regression model using all 18 variables. The rankings - indicating the variable 
importance - were calculated based on the residual deviances of the variables 
included into the model. Next, the least significant variable was eliminated from 
the model and  the model with the remaining 17 candidate predictors was fit. This 
procedure was repeated until one variable was left in the model (cfr. backward 
selection). For each model, the prediction accuracy was calculated using the held-
back sample of the current iteration. In a final step, the average performance was 
calculated over all 10 cross-validation samples and the model with the highest 
average prediction accuracy was selected. 
 
 
7.3 Results 
 
7.3.1 Poly substance use and drug-related behaviour  
 
Sixty-four percent of the combined sample (n=211) reported recent poly-drug use 
(last 30 days).  
 In terms of drug and alcohol use ever and during the last 30 days, no differences 
were found for the use of alcohol (both every amount and excessive use) between 
both groups. For drugs, a significantly higher prevalence of use was reported for 
all substances, except for hallucinogens (ever and recent use), ecstasy (recent use) 
and buprenorphine (recent use) in the group of poly substance users. However, 
buprenorphine and hallucinogens were only used by a limited number of 
individuals in both groups. In general, poly substance users have been significantly 
more in treatment for drug problems than single drug users (p = .000) (22.0% - 
48.3%). In accordance with the findings on past and recent alcohol use, no 
differences were found with regard to treatment history for alcohol problems. 
Injecting drugs occurred less frequently (7.7%) in the group of single drug users, 
while almost a quarter (24.2%) of the poly substance users (24.2%) had ever 
injected drugs (p=.000). 
 
Table 1: Comparison of drug and alcohol use ever and during the last 30 days (according to ASI 
definition) between single and poly substance users 
 EVER   RECENT   
 
Single 
N=118 
Poly 
N=211 
Pearson 
Chi² 
P 
Single 
N=118 
Poly 
N=211 
Pearson 
Chi² 
P 
 
 
        
Alcohol 
(every amount) (%) 
95.8 96.2 .040 .842 76.1 84.4 3.418 .064 
Alcohol  
(>= five glasses) (%) 
88.1 90.0 .291 .590 66.9 73.9 1.809 .179 
Cannabis (%) 22.0 45.5 17.858 .000** 3.4 30.3 33.502 .000** 
Heroin (%) 11.9 30.3 14.269 .000** .8 21.3 26.391 .000** 
Methadone (%) 7.6 24.6 14.511 .000** 2.5 19.0 17.948 .000** 
Buprenorphine (%)  1.7 6.6 3.992 .046* .8 1.9 .556 .456 
Other opiates (%) 6.8 22.7 13.664 .000** .0 5.7 6.965 .005** 
Benzodiazepines (%) 41.5 76.3 39.646 .000** 11.0 63.5 84.358 .000** 
Antidepressants %) 33.9 71.1 42.903 .000** 7.6 51.2 62.657 .000** 
Cocaine (%) 18.6 36.0 10.924 .001** 2.5 22.7 23.590 .000** 
Amphetamines (%) 16.9 33.2 10.027 .002** 1.7 11.4 9.742 .002** 
Hallucinogens (%) 7.6 14.2 3.146 .076 .0 1.7 1.799 .296 
Ecstasy (%) 14.4 28.9 8.801 .003** .8 4.3 3.000 .102 
         
* p < .05; ** p < .01 
 
When looking at the severity ratings of the EuropASI single drug users had 
significantly higher severity scores for the domain alcohol use, while poly 
 substance users reported worse scores for the domains ‘employment’, ‘drug 
problems’, ‘legal problems’ and ‘psychological health’. Comparable findings 
were retrieved when looking at the ASI composite scores, however no significant 
differences were found for the composite score of alcohol use in favour of the poly 
substance users. 
 
Table 2: severity rating on all domains of the EuropASI: comparison between single and poly 
substance users 
 
 
Single 
N=118 
Poly 
N=211 
T-value 
 
Df P 
      
Medical Problems 
[SD] 
2.51 
[2.13] 
2.62 
[2.33] 
-.414 
 
327 .679 
Employment, Education, Income Problems 
[SD] 
2.73 
 [2.10] 
3.46 
[2.05] 
-3.052 
 
320 .002** 
Alcohol Problems 
[SD] 
5.47 
[2.36] 
4.69 
[2.61] 
2.750 
 
263.297 .006** 
Drug Problems 
[SD] 
1.64 
[2.65] 
3.75 
[3.03] 
-6.550 
 
270.293 .000** 
Legal Problems 
[SD] 
1.33 
[1.90] 
2.09 
[2.18] 
-3.317 
 
270.962 .001** 
Family and Social Problems 
[SD] 
3.48 
[2.08] 
3.62 
[1.91] 
-.609 
 
327 .543 
Psychological Problems 
[SD] 
1.33 
[1.90] 
2.09 
[2.18] 
-5.165 
 
327 .001** 
      
* p < .05; ** p < .01 
 
 
Table 3: Composite scores on all domains of the EuropASI: comparison between single and poly 
substance users 
 
Single 
N=118 
Poly 
N=211 
T-value 
 
Df P 
      
Medical Problems 
[SD] 
.23 
[.31] 
.26 
[.34] 
-.832 
 
326 .406 
Employment, Education, Income Problems 
(economic situation) [SD] 
.62 
 [.44] 
.78 
[.37] 
-3.436 
 
206.361 .001** 
Employment, Education, Income Problems 
(satisfaction work  situation) [SD] 
.21 
 [.29] 
.21 
[.30] 
.130 
 
298 .896 
Alcohol Problems 
[SD] 
.45 
[.30] 
.45 
[.33] 
.103 
 
256.807 .918 
Drug Problems 
[SD] 
.05 
[.11] 
.16 
[.14] 
-7.714 
 
292.972 .000** 
Legal Problems 
[SD] 
.08 
[.15] 
.16 
[.22] 
-3.573 
 
311.721 .000** 
 Family Problems 
[SD] 
.15 
[.20] 
.19 
[.22] 
-1.942 
 
311 .053 
Social Problems 
[SD] 
.09 
[.18] 
.11 
[.17] 
-.599 
 
321 .550 
Psychological Problems 
[SD] 
.25 
[.23] 
.38 
[.22] 
-5.430 
 
327 .000** 
* p < .05; ** p < .01 
 
 
7.3.2 Sociodemographic and social characteristics 
 
Table 4 demonstrates the sociodemographic characteristics of both groups. Poly 
substance users were significantly younger, were less often employed and lived 
more often from a health insurance benefit, were less often married and lived more 
often with family, friends or in varying living situations compared with single drug 
users. Poly substance users lived more often with someone with an alcohol 
problem compared with single drug users. No significant differences were found 
with regard to living with someone with a drug problem, satisfaction with leisure 
time and number of close friends.  
Poly substance users had a more severe legal situation, with a significantly higher 
mean number of convictions, more legal problems in the past, and a higher number 
of individuals on probation.  
With regard to their physical health poly substance users have been significantly 
more hospitalized for medical complaints compared with single drug users (p = 
.007). However, when looking at chronic and recent medical complaints no 
significant differences were retrieved between both groups.  
 Table 4: Comparison of sociodemographic characteristics between single and poly substance 
users 
 
Characteristics 
Single 
N=118 
Poly 
N=211 
Pearson Chi² 
or T-value 
Df P 
      
Mean age  
[SD] 
42.20  
[10.86] 
39.34  
[11.40] 
2.221 
 
327 .027* 
      
Men (%) 74.6 71.1 .460  .498 
      
Civil status (%)   10.192  .006** 
-    Married ˆ 28.0 14.2    
-    Divorced 29.7 29.9    
-    Single ˆ 42.4 55.9    
      
Highest degree of education (%)   .089  .957 
- Primary or none 19.5 20.9    
- Secondary 61.0 60.2    
- Higher 19.5 19.0    
      
Living situation last 30 days (%)   13.950  .007** 
- With partner and/or child(ren) 40.7 31.8    
- With parents or other family ˆ 8.5 17.1    
- Alone 25.4 26.5    
- In controlled environment 25.4 19.0    
- With friends or in varying living situations ˆ .0 5.7    
      
Legal situation last 30 days (%)   19.978  .001** 
-    None ˆ 70.3 46.4    
-   None, but legal problems in the past ˆ 7.6 22.7    
-   Case pending/On bail 11.9 16.1    
-   Probation/Parole ˆ 3.4 5.2    
-   Other 6.8 9.5    
      
Mean number of convictions 
[SD] 
0.43 
[1.34] 
1.00 
[2.02] 
-3.034 
 
317.751 .003** 
      
Working situation last 30 days (%)   18.489  .001** 
- Part-time or full-time employed ˆ 36.8 17.7    
- Health insurance benefits ˆ 22.2 35.9    
- Unemployed 22.2 31.1    
- Other (student; retired; …) 4.3 4.3    
- In controlled environment 14.5 11.0    
      
Mean number of working days last 30 days  
[SD] 
6.85 
[9.34] 
3.77 
[7.89] 
3.024 
 
210.230 .003** 
Mean number of hospital admissions ever 
[SD] 
2.71 
[2.59] 
 
3.79 
[4.62] 
-2.703 
 
326.997 .007** 
* p < .05; ** p < .01 
 
 
 
 
 7.3.3 Psychological problems, prevalence of Axis I mood and 
anxiety disorders and Axis II personality disorders 
 
Based on the findings of the EuropaASI, poly substance users experienced 
significantly more feelings of depression (ever), difficulties in understanding, 
concentration and remembering (ever and last 30 days) and reported a higher 
percentage of prescribed medication for psychological problems (ever and last 30 
days). Generally, poly substance users reported a higher number of days with 
psychological problems in the last month. Furthermore, poly substance users were 
at higher risk for suicide, since they had significantly more serious thoughts of 
suicide (ever and last 30 days), and a significantly higher prevalence and mean 
number of suicide attempts. However, no significant differences were found 
between both groups regarding physical, sexual, or emotional abuse, ever or in the 
last 30 days and no differences were found regarding their treatment history 
(outpatient and inpatient) for psychological problems.  
 Table 5: Recent (last 30 days) and past psychological and emotional problems: comparison between single and poly substance users 
 EVER   RECENT   
 
Single 
N=118 
Poly 
N=211 
Pearson Chi² 
or  
T-value 
 
P Single 
N=118 
Poly 
N=211 
Pearson 
Chi² or  
T-value 
 
P 
         
Psychological problems (%)         
- Depression 61.9 73.5 4.783 .029* 30.5 40.8 3.408 .065 
- Anxiety or tension 67.8 70.6 .284 .594 43.2 46.9 .417 .518 
- Trouble understanding, concentration, remembering 29.7 46.0 8.380 .004** 25.4 38.9 6.087 .014* 
- Hallucinations  10.2 13.3 .681 .409 1.7 4.7 1.996 .158 
- Trouble controlling violent behaviour 42.4 46.4 .507 .476 16.9 21.3 .915 .339 
- Prescribed medication for psychological problems 60.2 82.9 20.798 .000** 27.1 72.0 61.950 .000** 
- Serious thoughts of suicide 39.0 53.6 6.435 .011* 11.0 28.0 12.711 .000** 
- Attempted suicide  23.7 40.3 9.198 .002** 3.4 5.2 .578 .447 
         
Mean number of suicide attempts  
[SD] 
0.32 
[.665] 
1.27 
[2.384] 
-5.412 
(df=263.368) 
.000**     
         
Mean number of days with psycho-emotional problems  
[SD] 
 
    10.83 
[12.65] 
16.07 
[12.66] 
-3.600 
(df=327) 
.000** 
* p < .05; ** p < .01 
 When looking at the prevalence of Axis I mood disorders, poly substance users 
reported significantly more often at least one mood disorder. When looking at the 
specific categories, a higher prevalence of depressive episodes was retrieved in the 
group of poly substance users. The same situation was found for anxiety disorders. 
Almost 60% of the poly substance users had experienced at least one anxiety 
disorder, compared with 34.3% of the single drug users (p = .000). Significantly 
higher prevalence rates were reported for all different anxiety disorders for poly 
substance users, except for specific phobia and panic disorder.  
 
Table 6: Prevalence of Axis I mood and anxiety disorders: comparison between single and poly 
substance users 
 
Single 
N=118 
Poly 
N=211 
Pearson  
Chi² 
P 
     
Mood disorders     
-    Depressive episode (%) 26.5 38.6 4.182 .041* 
-    Manic episode (%) 1.0 1.2 .021 1.000 
-    Dysthymia (%) 6.7 15.9 3.528 .060 
     
Anxiety disorders     
-    Panic Disorder (%)  2.9 7.0 2.045 .153 
-    Agoraphobia (%) 5.9 14.0 4.341 .037* 
-    Social phobia (%) 6.9 15.2 4.184 .041* 
-    Specific phobia (%) 4.5 8.0 1.134 .287 
-    Obsessive-compulsive disorder (%) 5.9 16.4 6.450 .011* 
-    Generalised anxiety disorder (%) 20.6 32.2 4.261 .039* 
-    Post-traumatic stress disorder (%)  1.0 10.0 8.392 .004** 
     
At least one mood disorder (%) 31.4 49.1 8.238 .004 
At least one anxiety disorder (%) 34.3 59.1 15.656 .000** 
     
* p < .05; ** p < .01 
 
Furthermore, when looking at the prevalence of Axis II personality disorders more 
than half of the poly substance users reported at least one personality disorder, 
which is significantly higher compared with 30.4% of the single drug users. With 
regard to the specific personality disorders, significantly higher scores were only 
reported in cluster B for borderline disorders in favour of the single drug users.  
 
 
 
 
 Table 7: Prevalence of Axis II personality disorders: comparison between single and poly 
substance users 
 Single 
N=118 
Poly 
N=211 
Pearson 
Chi² 
P 
     
Paranoid PD (%) 7.8 10.6 .667 .414 
Schizoid PD (%) 5.2 6.3 .150 .698 
Schizotypical PD (%) 4.4 4.3 .000 .987 
Antisocial PD (%) 7.0 14.0 3.616 .057 
Borderline PD (%) 15.7 35.3 14.028 .000** 
Histrionic PD (%) 1.8 2.4 .151 1.000 
Narcissistic PD (%) .0 2.9 3.397 .092 
Avoidant PD (%) 12.2 13.5 .119 .730 
Dependent PD (%) 5.3 7.7 .700 .403 
Obsessive-Compulsive PD (%) 10.4 9.7 .049 .824 
[ Depressive ] (%) 7.0 8.2 .163 .687 
[ Passive-Aggressive ] (%) 2.6 4.9 .958 .392 
     
Cluster A (%) 11.4 16.9 1.752 .186 
Cluster B (%) 18.4 41.5 17.691 .000 
Cluster C (%) 18.4 23.2 .990 .320 
At least one PD (%) 30.4 50.7 12.385 .000** 
     
* p < .05; ** p < .01 
 
 
7.3.4 Sociodemographic, drug and mental health related variables 
predicting poly substance use 
 
A binary logistic regression was carried out to investigate which variables predict 
poly substance use in the last 30 days. Data of 309 unique individuals were entered 
in the analysis. A test of the full model (79.9%) versus a model with intercept only 
(64.4%) was statistically significant: χ²(df=16) = 122.174, p<.000. Three variables 
emerged in the best fit model as significant determinants for clients to belong to 
the poly substance use group (cf. Table 8). Employment status (p = .008), the ASI 
composite score for psychological health (p = .001) and the ASI composite score 
for drugs (p = .000). The 1.302 odds ratio for the ASI composite score for 
psychological health and the 2.379 odds ratio for the ASI composite score for 
drugs indicate that the odds of belonging to the poly substance use group increase, 
for each unit increase on the ASI psychological health and drug composite score 
(95% C.I.: 1.115 to 1.521; p=.001 and 95% C.I.: 1.709 to 3.312; p<.001). The odds 
ratios of the employment status dummy variables compare each status except 
employed, to the status employed. For the health insurance benefit status, the 4.269 
 odds ratio means that the odds of belonging to the poly substance use group for 
individuals on health insurance are 4.269 times higher than for those of employed 
individuals (95% C.I.: 1.874 to 9.725; p=.001). The predictor living situation 
approached significance (p=.097) and the .290 odds ratio means that the odds of 
belonging to the poly substance use group for individuals in a controlled 
environment are only .290 times those of individuals living with partner and/or 
children (95% C.I.: .102 to .824; p=.020). Although there is no main effect of legal 
status (p=.195), the 3.236 odds ratio for legal problems in the past means that the 
odds of belonging to the group of poly substance users for individuals with no 
current legal problems, but legal problems in the past are 3.236 times higher than 
for those who have no legal history (95% C.I.: 1.178 to 8.887; p=.023). 
Furthermore, the number of hospital admissions ever approached significance, 
whereby a higher number of hospital admissions results in a higher chance of 
belonging to the group of poly substance users (95% C.I.: .996 to 1.207; p=.060). 
 Table 8: Binary logistic regression predicting membership of the poly substance use group (compared to the single drug use group) (N=309) 
 
       95% C.I. for Exp(B) 
 B S.E. Wald Df p-value Exp(B) Lower Upper 
         
Employment status (Ref. cat.: part-time or full-time employed)   13.663 4 .008**    
- health insurance benefits 1.451 .420 11.935 1 .001** 4.269 1.874 9.725 
- unemployed .566 .447 1.602 1 .206 1.761 .733 4.232 
- other (student, retired) 1.410 .728 3.755 1 .053 4.096 .984 17.051 
- controlled environment .652 .685 .905 1 .341 1.919 .501 7.345 
Legal situation (Ref. cat.: no legal situation)   6.095 4 .195    
- legal problems in the past 1.174 .516 5.188 1 .023* 3.236 1.178 8.887 
- case pending / on bail .589 .454 1.682 1 .195 1.803 .740 4.392 
- probation / parole .584 .816 .513 1 .474 1.793 .362 8.876 
- other .384 .629 .372 1 .542 1.468 .428 5.037 
Living situation (Ref. cat.: living with partner and/or children)   6.313 3 .097    
- family, friends, varying living situations -.278 .534 .270 1 .603 .758 .266 2.159 
- alone .077 .382 .041 1 .840 1.080 .511 2.286 
- controlled environment -1.237 .533 5.396 1 .020 .290 .102 .824 
At least one mood disorder .359 .342 1.099 1 .295 1.432 .732 2.800 
Number of hospitalisations for physical complaints .092 .049 3.537 1 .060 1.097 .996 1.207 
Number of suicide attempts .215 .162 1.762 1 .184 1.239 .903 1.702 
ASI composite score psychological problems .264 .079 11.136 1 .001** 1.302 1.115 1.521 
ASI composite score drugs .867 .169 26.351 1 .000** 2.379 1.709 3.312 
Constant -2.329 .437 28.378 1 .000 .097   
         
* p < .05; ** p < .01 
 
 7.4 Discussion 
 
The findings of this study demonstrate that poly substance use is the rule rather than an exception. At least 64% 
of the clients currently in treatment for substance abuse problems reported recent poly substance use in the last 
month. One can assume that this number is even an underestimation of reality, since a number of the individuals 
included in the study have been living in a controlled environment the last 30 days, making it less easy to use 
several substances at the same day. Considering this finding one might question the tendency in substance abuse 
treatment to focus on the primary substance of abuse. This substance specific point of view ignores the complexity 
of the situation of substance users, who often use different substances in the same time frame. 
The results of the bivariate analyses demonstrate that poly substance users generally have more severe problems 
than single drug users. These difficulties are not limited to their drug use, but affect a large number of social 
dimensions in their life (e.g. family situations, legal status, employment) often interfering with their recovery 
process. 
One of the goals of this study was to get insight in the psychological health of poly substance users. When looking 
at the findings of the domain psychological health of the EuropASI we see that poly substance users are at higher 
risk for committing suicide compared with single drug users, and report a higher number of days with 
psychological problems. The fact that 72% of the poly substance users got medication prescribed for psychological 
problems during the last month also illustrates worse psychological health in the group of poly substance users. 
The scores of the diagnostic instruments confirm these findings, illustrating that poly substance users significantly 
more often experienced mood and anxiety disorders, as well as personality disorders, resulting in a high prevalence 
of co-occurring psychiatric problems.   
Further analyses of the above mentioned findings by use of binary logistic regression demonstrated a strong impact 
of psychological health, intensity of drug problems and employment status on poly substance use. However, it was 
the ASI composite score for psychological health, not the diagnostic instruments used to measure personality, and 
mood an anxiety disorders that showed an impact on poly substance use. Poly substance users reported a higher 
number of days with psychological problems in the last month, and a higher percentage of individuals with 
prescribed medication for psychological problems. This finding demonstrates that rather the psychological 
complaints as reported by the client, than the presence of psychiatric disorders (as defined by the DSM-IV) have 
an impact on belonging to the group of poly substance users. Therefore, we urge for more attention to patient 
reported measures and instruments, based on clients’ own experiences, rather than focusing on the presence or 
absence of a diagnosed disorder.  
 
 
7.4.1 Limitations of the study 
 
This study highlights the prevalence of poly substance use in a varied sample of drug users, seeking treatment for 
drug abuse problems. However, the dispersion of the sample is rather unequally divided. The majority of the 
sample (83.3%) consisted of individuals seeking treatment in specific psychiatric units, with a large number of 
individuals mainly suffering from alcohol dependence. 
 Second, despite the fact that the co-occurrence of psychological problems and drug abuse problems has clear 
clinical implications, the cross-sectional character of the study limits the possibility to investigate the relationship 
between cause or consequences of poly substance use and poor mental health.  
Finally, the lack of a clear definition on the concept of ‘poly substance use’ hampers the comparison with 
(inter)national data on this subject. It results in conflicting findings, limiting the availability of concrete assistance 
for clinical practice. 
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